Johnson & Johnson (NYSE:JNJ) unveiled compelling data from a Phase 3 study featuring the dynamic duo of Rybrevant and Lazcluze. The study showcased a robust overall survival trend that outshone AstraZeneca’s Tagrisso in combatting a specific strain of lung cancer.

Known as MARIPOSA, the study unveiled a significant milestone at the three-year mark, with a median follow-up of 31.1 months. Impressively, 61% of patients treated with the Rybrevant-Lazcluze combo remained alive, surpassing the 53% survival rate of those on the Tagrisso regimen.

The trial focused on patients battling advanced non-small cell lung cancer, armed with epidermal growth factor receptor (EGFR) exon 19 deletions or L858R substitution mutations.

Additionally, ongoing assessments are probing the depths of overall survival, with extended follow-ups serving as a critical secondary benchmark. Progression-free survival stands out as the primary efficacy measure under scrutiny.

Lazcluze, also recognized as lazertinib, emerged from a collaborative effort between J&J and YuHan. Notably, the FDA gave the green light for the Rybrevant-Lazcluze combination in treating EGFR-mutated non-small cell lung cancer towards the tail end of August.